Literature DB >> 17118233

Diabetic nephropathy: worldwide epidemic and effects of current treatment on natural history.

Peter Rossing1.   

Abstract

Diabetic nephropathy has become a worldwide epidemic, accounting for approximately one third of all cases of end-stage renal disease. With increasing prevalence of diabetes particularly in Asia, and a global prevalence of microalbuminuria of 39%, the problem is expected to grow. Improved management of diabetes aimed at improved glycemic control, to avoid initiation of diabetic nephropathy, and antihypertensive treatment blocking the renin-angiotensin system, to avoid its progression, need to be implemented, particularly in high-risk patients.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17118233     DOI: 10.1007/s11892-006-0083-y

Source DB:  PubMed          Journal:  Curr Diab Rep        ISSN: 1534-4827            Impact factor:   4.810


  41 in total

1.  An alarmingly high prevalence of diabetic nephropathy in Asian type 2 diabetic patients: the MicroAlbuminuria Prevalence (MAP) Study.

Authors:  A Y T Wu; N C T Kong; F A de Leon; C Y Pan; T Y Tai; V T F Yeung; S J Yoo; A Rouillon; M R Weir
Journal:  Diabetologia       Date:  2004-12-23       Impact factor: 10.122

2.  Long-term juvenile diabetes treated with unmeasured diet.

Authors:  H C Knowles
Journal:  Trans Assoc Am Physicians       Date:  1971

3.  The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes.

Authors:  H H Parving; H Lehnert; J Bröchner-Mortensen; R Gomis; S Andersen; P Arner
Journal:  N Engl J Med       Date:  2001-09-20       Impact factor: 91.245

4.  Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators.

Authors: 
Journal:  Lancet       Date:  2000-01-22       Impact factor: 79.321

Review 5.  The changing epidemiology of diabetic microangiopathy in type 1 diabetes.

Authors:  P Rossing
Journal:  Diabetologia       Date:  2005-06-29       Impact factor: 10.122

6.  Chronic kidney disease and its prevention in India.

Authors:  Sanjay K Agarwal
Journal:  Kidney Int Suppl       Date:  2005-09       Impact factor: 10.545

7.  Improved prognosis in type 1 diabetic patients with nephropathy: a prospective follow-up study.

Authors:  Anne Sofie Astrup; Lise Tarnow; Peter Rossing; Lotte Pietraszek; Peter Riis Hansen; Hans-Henrik Parving
Journal:  Kidney Int       Date:  2005-09       Impact factor: 10.612

8.  Incidence of ESRD and survival after renal replacement therapy in patients with type 1 diabetes: a report from the Allegheny County Registry.

Authors:  Rimei Nishimura; Janice S Dorman; Zsolt Bosnyak; Naoko Tajima; Dorothy J Becker; Trevor J Orchard
Journal:  Am J Kidney Dis       Date:  2003-07       Impact factor: 8.860

9.  Early aggressive antihypertensive treatment reduces rate of decline in kidney function in diabetic nephropathy.

Authors:  H H Parving; A R Andersen; U M Smidt; P A Svendsen
Journal:  Lancet       Date:  1983-05-28       Impact factor: 79.321

10.  Long-term antihypertensive treatment inhibiting progression of diabetic nephropathy.

Authors:  C E Mogensen
Journal:  Br Med J (Clin Res Ed)       Date:  1982-09-11
View more
  40 in total

1.  A dual COX-2/sEH inhibitor improves the metabolic profile and reduces kidney injury in Zucker diabetic fatty rat.

Authors:  Md Abdul Hye Khan; Sung Hee Hwang; Amit Sharma; John A Corbett; Bruce D Hammock; John D Imig
Journal:  Prostaglandins Other Lipid Mediat       Date:  2016-07-16       Impact factor: 3.072

2.  Coptisine ameliorates renal injury in diabetic rats through the activation of Nrf2 signaling pathway.

Authors:  Jiajia Zhai; Zeping Li; Huifeng Zhang; Louyan Ma; Zhengquan Ma; Yi Zhang; Jian Zou; Mo Li; Li Ma; Xiaomiao Li
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2019-08-16       Impact factor: 3.000

3.  Reduced beta 2 glycoprotein I improves diabetic nephropathy via inhibiting TGF-β1-p38 MAPK pathway.

Authors:  Tong Wang; Si-Si Chen; Rui Chen; De-Min Yu; Pei Yu
Journal:  Int J Clin Exp Pathol       Date:  2015-03-01

4.  End-Stage Kidney Diseases in Immigrant Groups: A Nationwide Cohort Study in Sweden.

Authors:  Per Wändell; Axel C Carlsson; Xinjun Li; Danijela Gasevic; Johan Ärnlöv; Jan Sundquist; Kristina Sundquist
Journal:  Am J Nephrol       Date:  2019-02-01       Impact factor: 3.754

5.  YAP mediates the interaction between the Hippo and PI3K/Akt pathways in mesangial cell proliferation in diabetic nephropathy.

Authors:  Xuan Qian; Linlin He; Meng Hao; Yuan Li; Xizhi Li; Yiqi Liu; Hong Jiang; Liu Xu; Chengcheng Li; Wenya Wu; Lei Du; Xiaoxing Yin; Qian Lu
Journal:  Acta Diabetol       Date:  2020-08-20       Impact factor: 4.280

Review 6.  Optimal therapy in hypertensive subjects with diabetes mellitus.

Authors:  Gianpaolo Reboldi; Giorgio Gentile; Fabio Angeli; Paolo Verdecchia
Journal:  Curr Atheroscler Rep       Date:  2011-04       Impact factor: 5.113

7.  Increased risk of CKD among type 2 diabetics with nonalcoholic fatty liver disease.

Authors:  Giovanni Targher; Michel Chonchol; Lorenzo Bertolini; Stefano Rodella; Luciano Zenari; Giuseppe Lippi; Massimo Franchini; Giacomo Zoppini; Michele Muggeo
Journal:  J Am Soc Nephrol       Date:  2008-04-02       Impact factor: 10.121

8.  Thirty-one novel biomarkers as predictors for clinically incident diabetes.

Authors:  Veikko Salomaa; Aki Havulinna; Olli Saarela; Tanja Zeller; Pekka Jousilahti; Antti Jula; Thomas Muenzel; Arpo Aromaa; Alun Evans; Kari Kuulasmaa; Stefan Blankenberg
Journal:  PLoS One       Date:  2010-04-09       Impact factor: 3.240

9.  Urocortin ameliorates diabetic nephropathy in obese db/db mice.

Authors:  X Li; J Hu; R Zhang; X Sun; Q Zhang; X Guan; J Chen; Q Zhu; S Li
Journal:  Br J Pharmacol       Date:  2008-04-21       Impact factor: 8.739

10.  Reduced beta 2 glycoprotein I improve diabetic nephropathy via inhibiting TGF-β1-p38 MAPK pathway.

Authors:  Tong Wang; Si-Si Chen; Rui Chen; De-Min Yu; Pei Yu
Journal:  Int J Clin Exp Med       Date:  2015-05-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.